Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Chemo Iberica, S.A. manufactures and distributes generic medicines. It offers pharmaceuticals; agrochemicals, including insecticides, fungicides, herbicides, and micronutrients for agrochemical formulations; oncology drugs; and veterinary drugs for nutrition and animal health, such as antibiotics, anthelmintics, antiinflammatory, antiparasities, coccidiostatic, and chemotherapeutical drugs. The company offers its products in Asian markets, including South Korea, the Philippines, Malaysia, Vietnam, Thailand, and Pakistan, as well as exported to European countries, the United States, South America, and Canada. It has a strategic alliance with Fosum Pharma. The company was founded in 1940 and is headquartered in Madrid, Spain with additional offices in Spain, Switzerland, Hungary, India, China, Italy, and Brazil. It has production facilities in Europe, Asia, and Latin America.

Nanjing Ruckus Pharmaceutical Co., Ltd., established on 2003-02-08, The business scope includes freeze-dried powder injection,Freeze-dried powder injection(anticancer drug),small volume injection,small volume injection(non-terminal sterilized),tablet,tablet(anticancer drug),Capsules,Capsules(anticancer drug),Granules,powder injection(Cephalosporins);API(Production according to the scope listed in the license);medicine,Biological Engineering,Healthy food,Technology development of medical devices,to promote,transfer,consultation service;Self-operated and agent import and export business of various commodities and technologies(Except for goods and technologies that are restricted by the state to operate or prohibited from importing and exporting).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Alcon Research Ltd., a subsidiary of Nestl�� SA, is a company headquartered in Huntington, WV, that manufactures optical goods.

Nanjing Ruckus Biomedical Co., Ltd., established on 2002-02-07, The business scope includes raw materials and various dosage forms(including but not limited to tablets,Capsules,aerosol,immune preparations,Granules,ointment,pill,oral liquid,inhalant,injection,Liniment,tincture,suppositories)pharmaceutical products(Including but not limited to chemical raw materials,Chemicals,Chinese herbal medicine,Chinese patent medicine,Chinese Herbal Medicine,biochemical drug,Biological product,Narcotic Drugs,Psychotropic drugs,toxic drugs for medical use[Compatible with business scope],vaccine),Health products,Research and development of medical devices and related products,manufacturing and sales;Chinese patent medicine,Chemical API,Chemicals,Antibiotic API,antibiotic preparation,Wholesale of biochemical drugs.Technology development of pharmaceuticals and medical devices,transfer,consult;business management,Financial Management Consulting;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Nanjing Ruckus Biomedical Research Co., Ltd., established on 2010-01-04, Business scope includes pharmaceuticals,medical instruments,Health food research and development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jiangsu Tianyishi Pharmaceutical Co., Ltd., established on 2008-08-29, The scope of business includes research and development of pharmaceuticals,technical consulting,Technical Services,technology transfer;API,tablet,Production of capsules;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Founder Pharmaceutical Research Institute Co., Ltd., established on 2008-09-04, Business scope includes research and development of pharmaceutical products(Except for pharmaceutical production),technology transfer,Technical Services,technical consulting;Investment;Technology Import and Export,Import and export.(After receiving this license,Need to report to the District Chamber of Commerce).(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

MSN Laboratories Pvt Ltd. is an Indian private company with domestic subsidiaries, that engages in research and development of pharmaceuticals.

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (doing business as Chia Tai Fenghai Pharmaceutical Co Ltd), a subsidiary of Sino Biopharmaceutical Ltd., is a company headquartered in Dafeng, China, that manufactures and distributes pharmaceutical products.

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, production and sales of medical devices and pharmaceuticals. It offers orthopedics, medical aesthetics, wound healing, hemostasis, ophthalmology and anti-adhesion products. The company mainly offers intraocular lens (IOL), ophthalmology and optometry end products, medical sodium hyaluronate, medical chitosan, medical collage sponge, rhEGF amd other related products. Shanghai Haohai Biological Technology was founded on January 24, 2007 and is headquartered in Shanghai, China.

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., established on 2001-08-31, Business scope includes pharmaceuticals,Research and Development of Disinfectants,production and sales(Operate according to the scope listed in the license,involved in the law,Do not operate if prohibited by laws and regulations,Operating with a license involved in operating with a license).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Wuyao Technology Co., Ltd., established on 2003-06-10, Business scope includes pharmaceutical,chemical industry,medical instruments,product technology development,technology transfer,Technical Services,technical consulting.

China Resources Saike Pharmaceutical Co., Ltd., part of China Resources Double-Crane Pharmaceutical Co., Ltd., is a Chinese company located in Beijing. The firm manufactures pharmaceutical products. It was founded in 1981. China Resources Double-Crane Pharmaceutical Co., Ltd. acquired China Resources Saike Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. on November 30, 2015 for $624.11 million.

Tianjin Kanghong Pharmaceutical Technology Development Co., Ltd., established on 2003-09-04, Business scope includes pharmaceutical,new material,Technology development of electronic information,consult,Serve,transfer;chemical industry(Dangerous goods and precursors are excluded),Computers and Peripherals,Electronic Component,Wholesale and retail of electrical equipment;Wholesale Prepackaged Food(Subject to food circulation license);Import and export of goods and technologies.(If the above business scope involves industry licensing, the license certificate,Operate within the validity period,If the country has special franchise regulations, it shall be handled in accordance with the regulations)

Rivopharm is a Swiss agency that focuses on the development, manufacture, and marketing of generic pharmaceutical products. Year after year, they expand by providing quality, customer-oriented services to their partners.